Real-world clinical experience with FreeFlex™ emulgel in osteoarthritis: Insights from a cross-sectional survey of orthopedician specialists

Abstract

Background: Osteoarthritis (OA) is the most common form of arthritis, significantly impacting quality of life due to chronic pain and reduced mobility. Although oral medications and intra-articular injections are commonly used, their long-term application is often limited by systemic side effects. Topical formulations offer a targeted approach with fewer adverse effects. FreeFlex™ Emulgel, incorporating VesiFuze™ technology, is designed to enhance skin penetration and deliver effective anti-inflammatory and analgesic benefits for localized pain relief. This survey-based study was conducted to evaluate healthcare professionals' preferences and perceptions regarding the topical use of FreeFlex™ Emulgel, which incorporates VesiFuze™ technology. Methods: A paper-based survey was conducted among orthopedicians to assess their experience with FreeFlex™ Emulgel. The questionnaire covered key aspects such as symptom relief, onset of action, safety profile, and patient adherence in comparison to other topical agents. Results: The survey revealed that 85.71% of orthopedicians prescribe FreeFlex™ Emulgel regularly, while 14.29% use it occasionally. In terms of effectiveness, 92.85% of respondents rated it as very good to excellent. Regarding patient outcomes, 78.57% observed significant pain relief, 54.29% noted improved mobility, and 51.43% reported enhanced patient satisfaction. Compared to other topical formulations, 55.71% rated it as significantly better, and 45.71% as superior. Furthermore, 95.71% of respondents indicated they would recommend FreeFlex™ Emulgel to their colleagues, citing its positive impact on patient care. Conclusion: FreeFlex™ Emulgel was highly regarded by orthopedicians for its effectiveness in pain relief and improving patient mobility and satisfaction.